Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study
YH Khor, M Schulte, KA Johannson… - European …, 2023 - Eur Respiratory Soc
Background Little is known about generalisability of randomised controlled trials (RCTs) for
idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to …
idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to …
Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
WA Wright, LE Crowley, D Parekh… - BMJ open …, 2021 - bmjopenrespres.bmj.com
Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …
[HTML][HTML] Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF …
JP Finnerty, A Ponnuswamy, P Dutta… - BMC Pulmonary …, 2021 - Springer
Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities
A Caminati, F Madotto, S Conti, G Cesana… - Internal and Emergency …, 2021 - Springer
Placebo arms of clinical trials provide an opportunity to investigate the natural history of
idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life …
idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life …
Clinical trials and tribulations—lessons from pulmonary fibrosis
AL Olson, JJ Swigris, KK Brown - QJM: An International Journal …, 2012 - academic.oup.com
Idiopathic pulmonary fibrosis (IPF) is a dreadful disease that lacks adequate therapy. A
number of treatment trials have been performed and have utilized a variety of primary …
number of treatment trials have been performed and have utilized a variety of primary …
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
J Behr, M Kreuter, MM Hoeper, H Wirtz… - European …, 2015 - Eur Respiratory Soc
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in
2011, we investigated clinical management practices for patients with IPF according to …
2011, we investigated clinical management practices for patients with IPF according to …
Pulmonary fibrosis, part II: state-of-the-art patient management
KC Meyer - Expert Review of Respiratory Medicine, 2017 - Taylor & Francis
Introduction: While many pharmacologic therapies for the treatment of idiopathic pulmonary
fibrosis (IPF) have been evaluated via randomized, placebo-controlled clinical trials (RCTs) …
fibrosis (IPF) have been evaluated via randomized, placebo-controlled clinical trials (RCTs) …
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
RM du Bois, D Weycker, C Albera… - American journal of …, 2011 - atsjournals.org
Rationale: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have
been described; however, there is a need for a practical and accurate method of quantifying …
been described; however, there is a need for a practical and accurate method of quantifying …
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
A Caminati, C Lonati, R Cassandro… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …
[HTML][HTML] Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials
CP Atkins, YK Loke, AM Wilson - Respiratory Medicine, 2014 - Elsevier
Background Most data on outcomes in Idiopathic Pulmonary Fibrosis (IPF) pre-dates current
guidelines. Data on rates of infection is sparse; the effect of low-dose corticosteroids and …
guidelines. Data on rates of infection is sparse; the effect of low-dose corticosteroids and …